GSK joins AstraZeneca, Boehringer in capping US out-of-pocket inhaler prices at $35 per month

GSK joins AstraZeneca, Boehringer in capping US out-of-pocket inhaler prices at $35 per month

Submitted by admin on March 21, 2024 - 6:37pm
Source: 
Fierce Pharma
News Tags: 
GSK
Boehringer Ingelheim
AstraZeneca
drug pricing
COPD
asthma
Headline: 
GSK joins AstraZeneca, Boehringer in capping US out-of-pocket inhaler prices at $35 per month
snippet: 

Amid congressional scrutiny on U.S. inhaler prices, GSK is the latest pharma giant to commit to capping patients' monthly payments for its portfolio of asthma and chronic obstructive pulmonary disease (COPD) meds.

Do Not Allow Advertisers to Use My Personal information